B-hCTLA4/hOX40 mice

Basic Information

Targeting Strategy

Details

Phenotype

Protein Expression Analysis

 

Splenocytes B-hCTLA4/hOX40 mice were analyzed by flow cytometry. Mouse CTLA4+ cells were detectable in WT C57BL/6, while human CTLA4+ cells were detectable in the homozygous B-hCTLA4/hOX40 mice.

Splenocytes from homozygous B-hCTLA4/hOX40 mice were analyzed by flow cytometry. Mouse OX40+ cells were detectable in wild type (WT) C57BL/6, while human OX40+ cells were detectable in the homozygous B-hCTLA4/hOX40 mice.

 

Application

Combination Therapy of CTLA4 mAb (Yervoy) and OX40 mAb

 

Murine colon cancer MC38 cells were subcutaneously implanted into homozygous B-hCTLA4/hOX40 mice.

Mice were grouped when the tumor size was approximately 150±50 mm³ (n=8). Anti-hCTLA4 antibody Yervoy and the anti-hOX40 antibody shows obviously inhibitory effects respectively. Combination of Anti-hCTLA4 antibody Yervoy and the anti-hOX40 antibody shows better inhibitory effects than single treatment, suggesting that  B-hCTLA4/hOX40 mouse is a powerful tool for in vivo evaluating combination therapy efficacy of hCTLA4 antibody and hOX40 antibody.

References

1. J Exp Med. 1991 Sep 1;174(3):561-9.
2. Immunol Cell Biol. 1999 Feb;77(1):1-10.
3. Blood. 2005 Nov 1;106(9):3127-33. Epub 2005 Jul 21.
4. Clin Transl Immunology. 2014 Aug 1;3(8): e22. doi: 10.1038/cti.2014.18. eCollection 2014 Aug.